Relay Therapeutics, Inc.
RLAY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | – | $677 | $7,679 | $0 |
| % Growth | – | -91.2% | – | – |
| Cost of Goods Sold | $748 | $0 | $0 | $0 |
| Gross Profit | -$748 | $677 | $7,679 | $0 |
| % Margin | – | 100% | 100% | – |
| R&D Expenses | $68,262 | $63,897 | $73,809 | $68,075 |
| G&A Expenses | – | $13,627 | $18,739 | $16,904 |
| SG&A Expenses | $11,381 | $13,627 | $18,739 | $16,904 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $79,643 | $77,524 | $92,548 | $84,979 |
| Operating Income | -$80,391 | -$76,847 | -$84,869 | -$84,979 |
| % Margin | – | -11,351.1% | -1,105.2% | – |
| Other Income/Exp. Net | $6,242 | $6,472 | $7,804 | $8,975 |
| Pre-Tax Income | -$74,149 | -$70,375 | -$77,065 | -$76,004 |
| Tax Expense | – | $0 | $0 | $0 |
| Net Income | -$74,149 | -$70,375 | -$77,065 | -$76,004 |
| % Margin | – | -10,395.1% | -1,003.6% | – |
| EPS | -0.43 | -0.41 | -0.46 | -0.45 |
| % Growth | -4.9% | 10.9% | -2.2% | – |
| EPS Diluted | -0.43 | -0.41 | -0.46 | -0.45 |
| Weighted Avg Shares Out | 172,389 | 171,265 | 169,233 | 167,338 |
| Weighted Avg Shares Out Dil | 172,389 | 171,265 | 169,233 | 167,338 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,407 | $7,105 | $7,813 | $8,974 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $748 | $1,002 | $1,208 | $1,334 |
| EBITDA | -$73,401 | -$75,845 | -$83,661 | -$83,645 |
| % Margin | – | -11,203.1% | -1,089.5% | – |